Last reviewed: May 15, 2026 Last updated: May 15, 2026 Written by: Jay Hastings , CEO of PlexusDx Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations
During the trial, additional anti-diabetic medication was initiated as an add on to randomized treatment by 10% and 4.3% of patients randomized to placebo and semaglutide tablets 14 mg, respectively
While Semaglutide might cause gastrointestinal issues, alternatives like liraglutide may cause similar effects, whereas orlistat is known for causing fatty stools
Higher doses have been linked with a rise in resting heart rate, and a few people developed irregular heart rhythms
475, no
7.4.4 Next-generation agonists The development of dual GLP-1/GIP receptor agonists (e.g., tirzepatide) and novel blood-brain barrier-penetrant formulations may offer superior neuroprotective efficacy by more potently engaging central receptors or providing a broader spectrum of action ( 7.5 Limitations of current evidence Several limitations must be considered when interpreting the current evidence
